Biotech Stock Tumble Stumps Analyst
April 11, 2014 | By Carly Helfand
Nobody quite knows why the Nasdaq biotech index ($IBB) sank another 5.6% on Thursday. Analysts do know that the drop came the day after the index jumped 4.1%, also inexplicably, which has added to their confusion. Some have suggested pricing concerns over Gilead's ($GILD) Sovaldi may be to blame for a broader downward trend. But others say biotech stocks have simply become vastly overpriced, causing trouble in the market. Article (sub. req.)
Thank You Fierce Pharma and Ms Helfand
All Together now, on 3, . . . 1, . . 2, . . . 3
"Awww . . . "